| __timestamp | AstraZeneca PLC | Blueprint Medicines Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 13324000000 | 7890000 |
| Thursday, January 1, 2015 | 11451000000 | 14456000 |
| Friday, January 1, 2016 | 9739000000 | 19218000 |
| Sunday, January 1, 2017 | 10543000000 | 27986000 |
| Monday, January 1, 2018 | 10362000000 | 47928000 |
| Tuesday, January 1, 2019 | 11848000000 | 96388000 |
| Wednesday, January 1, 2020 | 11693000000 | 157743000 |
| Friday, January 1, 2021 | 15680000000 | 195293000 |
| Saturday, January 1, 2022 | 18955000000 | 237374000 |
| Sunday, January 1, 2023 | 18025000000 | 295141000 |
| Monday, January 1, 2024 | 20532000000 | 359272000 |
Cracking the code
In the ever-evolving pharmaceutical landscape, understanding the strategic allocation of resources is crucial. Over the past decade, AstraZeneca PLC and Blueprint Medicines Corporation have demonstrated contrasting approaches in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has consistently invested heavily in SG&A, with a peak in 2022, spending nearly 90% more than in 2014. This reflects their expansive market reach and robust operational strategies. In contrast, Blueprint Medicines, a burgeoning biotech firm, has shown a remarkable growth trajectory, with SG&A expenses increasing by over 3,600% from 2014 to 2023. This surge underscores their aggressive expansion and commitment to innovation. As the industry continues to evolve, these spending patterns offer a glimpse into the strategic priorities of established giants and emerging innovators.
Cost Management Insights: SG&A Expenses for Johnson & Johnson and AstraZeneca PLC
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and United Therapeutics Corporation
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and HUTCHMED (China) Limited
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends